Transcatheter tricuspid valve‐in‐valve implantation for degenerative surgical bio‐prosthesis using SAPIEN 3: A case series

We evaluated early outcomes of transcatheter valve‐in‐valve (ViV) implantation in patients with degenerated bio‐prosthesis in tricuspid position. Total of 5 patients were included in our case series. Baseline native tricuspid valve etiology were highly varied ranging from chest wall trauma, Ebstein anomaly, rheumatic heart disease, infective endocarditis and complex congenital heart disease. These differences also made patient comorbidities highly varied. Procedure details were also varied due to different clinical and technical challenges. All cases underwent successful Tricuspid VIV implantation with satisfactory hemodynamics results. All patients experienced improved clinical symptoms at follow up.
Transcatheter tricuspid valve‐in‐valve for patients with failed tricuspid bio‐prosthesis can be performed successfully and safely in broad variety of patients with varied underlying tricuspid valve pathology and patient comorbidities. The procedure opens new option for surgical valve selection in patients that required tricuspid valve surgery at young age.